BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 18417314)

  • 1. Gastrointestinal perforation in metastatic carcinoma: a complication of bevacizumab therapy.
    Collins D; Ridgway PF; Winter DC; Fennelly D; Evoy D
    Eur J Surg Oncol; 2009 Apr; 35(4):444-6. PubMed ID: 18417314
    [No Abstract]   [Full Text] [Related]  

  • 2. [Surgical management of bevacizumab-associated peritonitis due to perforation].
    Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
    Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoscopic management of colonic perforation owing to angiogenesis inhibitors.
    Ezzedine S; Bege T; Berdah S; Vitton V; Grimaud JC; Barthet M
    Surg Laparosc Endosc Percutan Tech; 2010 Dec; 20(6):e230-2. PubMed ID: 21150409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
    Heinzerling JH; Huerta S
    Curr Surg; 2006; 63(5):334-7. PubMed ID: 16971205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
    Han ES; Monk BJ
    Gynecol Oncol; 2007 Apr; 105(1):3-6. PubMed ID: 17383545
    [No Abstract]   [Full Text] [Related]  

  • 6. Gastrointestinal perforation due to bevacizumab in colorectal cancer.
    Saif MW; Elfiky A; Salem RR
    Ann Surg Oncol; 2007 Jun; 14(6):1860-9. PubMed ID: 17356952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing patients treated with bevacizumab combination therapy.
    Gordon MS; Cunningham D
    Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bevacizumab (Avastin) related surgical complications: comment to Abbrederis K et al. (2007)].
    Lordick F; Siewert JR
    Chirurg; 2008 Apr; 79(4):356-60. PubMed ID: 17453166
    [No Abstract]   [Full Text] [Related]  

  • 9. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
    Scappaticci FA; Fehrenbacher L; Cartwright T; Hainsworth JD; Heim W; Berlin J; Kabbinavar F; Novotny W; Sarkar S; Hurwitz H
    J Surg Oncol; 2005 Sep; 91(3):173-80. PubMed ID: 16118771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intricacies of bevacizumab-induced toxicities and their management.
    Gressett SM; Shah SR
    Ann Pharmacother; 2009 Mar; 43(3):490-501. PubMed ID: 19261963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events in bevacizumab and chemotherapy: patient management.
    Blowers E; Hall K
    Br J Nurs; 2009 Apr 9-22; 18(7):424-8. PubMed ID: 19373187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of bevacizumab in patients with metastatic breast cancer.
    Hamilton EP; Blackwell KL
    Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Generation mechanisms and management strategies of adverse reactions to Bevacizumab during cancer treatment].
    Ge FJ; Xu JM
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):481-6. PubMed ID: 21029688
    [No Abstract]   [Full Text] [Related]  

  • 14. GI perforation associated with bevacizumab.
    Yoon SS; Rivera R; Shah A; Ozden N
    Gastrointest Endosc; 2012 Jun; 75(6):1286-7. PubMed ID: 21862004
    [No Abstract]   [Full Text] [Related]  

  • 15. [A case of metachronous gastrointestinal perforation of a patient with metastatic rectal cancer during treatment with bevacizumab-based chemotherapy].
    Sadatomo A; Koinuma K; Miki A; Horie H; Yasuda Y
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):943-5. PubMed ID: 23863742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.
    Wu S; Keresztes RS
    Cancer Invest; 2011 Aug; 29(7):460-71. PubMed ID: 21740083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
    Richardson DL; Backes FJ; Hurt JD; Seamon LG; Copeland LJ; Fowler JM; Cohn DE; O'Malley DM
    Gynecol Oncol; 2010 Jul; 118(1):47-51. PubMed ID: 20382413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab-induced bowel perforation.
    Sliesoraitis S; Tawfik B
    J Am Osteopath Assoc; 2011 Jul; 111(7):437-41. PubMed ID: 21803880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of delayed colonic perforation after metallic stent placement for advanced descending colon cancer during bevacizumab-based chemotherapy].
    Tanaka I; Hisai H; Miyazaki E; Ono M; Maeda Y; Sato M; Kawasaki R; Gyobu H; Nakajima S; Yamada S; Muramatsu H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2319-21. PubMed ID: 22202368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.